Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14573781 | 0.94 | PTGER4 (0.33) | IDH1PTGER4CACNA2D1KAT2B | |
| SCHEMBL14573780 | 0.92 | TDP1 (0.33) | IDH1PTGER4CACNA2D1KAT2B | |
| SCHEMBL14607607 | 0.92 | IDH1 (0.32) | IDH1PTGER4CACNA2D1KAT2B | |
| SCHEMBL12378082 | 0.91 | IDH1 (0.34) | IDH1PTGER4CACNA2D1KAT2B | |
| SCHEMBL14573777 | 0.89 | IDH1 (0.34) | IDH1PTGER4CACNA2D1KAT2B | |
| SCHEMBL14573782 | 0.89 | HTT (0.36) | CACNA2D1 | |
| SCHEMBL14573778 | 0.89 | IDH1 (0.34) | IDH1PTGER4CACNA2D1KAT2B | |
| SCHEMBL12378100 | 0.88 | PTGDR2 (0.32) | IDH1PTGER4CACNA2D1 | |
| SCHEMBL12378101 | 0.86 | IDH1 (0.33) | IDH1PTGER4CACNA2D1 | |
| SCHEMBL12378113 | 0.86 | TP53 (0.35) | IDH1PTGER4CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072831-A1 | Integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072831-A1 | Integrase inhibitor compounds | TYMP, CDKN1A, PAICS | IDH1 104/4885PTGER4 3914/4885AGTR2 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.